2-(2-氨乙基)苯并咪唑二盐酸盐 | 4499-07-4

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 2-(2-氨乙基)苯并咪唑二盐酸盐
• 中文别名: 1H-苯并咪唑-2-乙胺二盐酸盐
• 英文名称: 2-(1H-Benzo[d]imidazol-2-yl)ethanamine dihydrochloride
• 英文别名: 2-(1H-benzimidazol-2-yl)ethanamine;dihydrochloride
• CAS: 4499-07-4；5620-45-1
• 化学式: C9H13Cl2N3
• 分子量: 234.12
• InChiKey: LKFGBWROFLZYQJ-UHFFFAOYSA-N

物化性质

• 熔点：
  235 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.91
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  54.7
• 氢给体数：
  4
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S26,S36/39
• 危险类别码：
  R22,R41
• WGK Germany：
  3
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H302,H319

反应信息

• 作为反应物：
  描述：

  2-(2-氨乙基)苯并咪唑二盐酸盐 、 N,N'-羰基二咪唑 以21%的产率得到
  参考文献：
  名称：

  BUSCHAUER, A.;SATTLER, H. -J.;SCHUNACK, W., CHEM. BER., 1984, 117, N 8, 2597-2614

  摘要：

  DOI：

文献信息

• Indolobenzazepine HCV NS5B inhibitors
  申请人：Bergstrom P. Carl

  公开号：US20070078122A1

  公开（公告）日：2007-04-05

  The invention encompasses compounds and salts of Formulas I, II, III, and IV as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

  这项发明涵盖了Formula I、II、III和IV的化合物和盐，以及使用这些化合物的组合物和方法。这些化合物对丙型肝炎病毒（HCV）具有活性，并可用于治疗感染HCV的患者。
• N-substituted cycloalkyl and polycycloalkyl .alpha.-substituted Trp-Phe-
  申请人：Warner-Lambert Company

  公开号：US05622983A1

  公开（公告）日：1997-04-22

  Novel unnatural dipeptoids of .alpha.-substituted Trp-Phe derivatives useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, colorectal tumors, or as antipsychotics are disclosed. Further the compounds are antianxiety agents, antiulcer agents, antidepressant agents, and are agents useful for preventing the withdrawal response produced by chronic treatment or use followed by chronic treatment followed by withdrawal from nicotine, diazepam, alcohol, cocaine, caffeine, or opiods. Also disclosed are pharmaceutical compositions and methods of treatment using the dipeptoids as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds to prepare pharmaceutical and diagnostic compositions.

  本发明涉及一种新颖的非天然二肽类α-取代Trp-Phe衍生物，可用作治疗肥胖症、肠道胃酸过多、胃泌素依赖性肿瘤、结肠癌或作为抗精神病药物。此外，这些化合物还具有抗焦虑、抗溃疡、抗抑郁作用，并可用于预防尼古丁、安定、酒精、可卡因、咖啡因或阿片类药物的长期治疗或使用后出现的戒断反应。本发明还涉及使用这些二肽类化合物制备药物和诊断组合物的方法。同时，本发明还涉及制备这些化合物的方法以及在制备中有用的新型中间体。
• N-substituted cycloalkyl and polycycloalkyl alpha-substituted Trp-Phe-
  申请人：Warner-Lambert Company

  公开号：US05278316A1

  公开（公告）日：1994-01-11

  Novel unnatural dipeptoids of .alpha.-substituted Trp-Phe derivatives useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further the compounds are antianxiety agents, antiulcer agents, antidepressant agents, and are agents useful for preventing the withdrawal response produced by chronic treatment or use followed by chronic treatment followed by withdrawal from nicotine, diazepam, alcohol, cocaine, caffeine, or opiods. Also disclosed are pharmaceutical compositions and methods of treatment using the dipeptoids as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds to prepare pharmaceutical and diagnostic compositions.

  本发明揭示了一种新型非天然二肽类α-取代Trp-Phe衍生物，可用作治疗肥胖症、肠道中胃酸过多、胃泌素依赖性肿瘤或抗精神病药物。此外，这些化合物还具有抗焦虑、抗溃疡、抗抑郁的作用，并可用于预防尼古丁、地西泮、酒精、可卡因、咖啡因或阿片类药物的慢性治疗或使用后的戒断反应。本发明还揭示了使用这些二肽类化合物制备药物和诊断组合物的方法。同时，还揭示了制备这些化合物的过程和制备中间体的新方法。
• Treatment of pain and colorectal cancer with dipeptoids of
  申请人：Warner-Lambert Company

  公开号：US05580896A1

  公开（公告）日：1996-12-03

  This invention relates to the treatment of pain and inhibiting the growth of colorectal cancer with dipeptoids of .alpha.-substituted Trp-Phe derivatives.

  本发明涉及使用α-取代的Trp-Phe二肽衍生物治疗疼痛和抑制结直肠癌生长。
• Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect
  申请人：Bayer Healthcare AG

  公开号：US20040186106A1

  公开（公告）日：2004-09-23

  The present invention relates to substituted phenylcyclohexanecarboxamides of the formula (I) having adenosine-uptake-inhibiting action, to a process for their preparation and to their use in medicaments, in particular for treating ischaemic brain disorders. 1

  本发明涉及公式（I）的取代苯基环己烷羧酰胺，具有腺苷摄取抑制作用，以及它们的制备过程和在药物中的使用，特别是用于治疗缺血性脑疾病。